Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
3 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.

Long- and short-term SSRI use contributes to increased hip fracture risk

07 Nov 2019

Treatment with selective serotonin reuptake inhibitors (SSRIs) in the short and long term appears to bear an increased risk of hip fracture, according to a recent study.

The case-control study used data from the US Renal Data System and included 4,912 maintenance haemodialysis patients with hip fracture and 49,120 nonfracture controls. All participants had >1 year of Medicare parts A and B coverage and >3 years of part D coverage.

During the 3-year part D coverage period, SSRI exposure was characterized as any (≥1 prescription filled), low, moderate and high use (<20 percent, 20 to <80 percent, and ≥80 percent of days covered by filled prescriptions, respectively).

On conditional logistic regression analysis, SSRI use conferred a 25-percent increase in hip fracture risk (adjusted odds ratio [OR], 1.25, 95 percent confidence interval [CI], 1.17–1.35). Risk estimates for fracture associated with any, low, moderate and high SSRI use were as follows: 1.25 (95 percent CI, 1.17–1.35), 1.20 (95 percent CI, 1.08–1.32), 1.31 (95 percent CI, 1.18–1.43) and 1.26 (95 percent CI, 1.12–1.41), respectively.

Researchers performed a separate examination of new short-term SSRI exposure in cases and controls with >18 months of part D coverage and no prior antidepressant use for 1 year. Results revealed a similar pattern of association with hip fracture risk (adjusted OR, 1.43, 95 percent CI, 1.23–1.67).

“The stronger association with new short-term use may suggest an acute mechanism potentially related to falls,” the researchers explained.

The study was limited by the inability to capture and account for biomarkers of mineral bone disorder.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
3 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.